Colestasis neonatal

1. Kelly DA, Stanton A. Jaundice in Babies: implications for community screening for biliary atresia. BMJ. 1995;310(6988):1172–1173

2. Feldman A, Suchy FJ. Approach to the infant with cholestasis. In: Suchy FJ, Sokol RJ, Balistreri WF, Bezerra JA, Mack CL, Shneider BL, eds. Liver Disease in Children. 5th ed. New York, NY: Cambridge University Press; 2014:107–115

3. Harpavat S, Finegold MJ, Karpen SJ. Patients with biliary atresia have elevated direct/conjugated bilirubin levels shortly after birth. Pediatrics. 2011;128(6):e1428–e1433

4. Harpavat S, Garcia-Prats JA, Shneider BL. Newborn bilirubin screening for biliary atresia. N Engl JMed. 2016;375(6):605–606

5. Harpavat S, Ramraj R, Finegold MJ, et al. Newborn direct or conjugated bilirubin measurements as a potential screen for biliary atresia. J Pediatr Gastroenterol Nutr. 2016;62(6):799–803

6.Harpavat S, Garcia-Prats JA, Anaya C, et al. Diagnostic yield of newborn screening for biliary atresia using direct or conjugated bilirubin measurements. JAMA. 2020;323(12):1141–1150

7. Hussein M, Howard ER, Mieli-Vergani G, Mowat AP. Jaundice at 14 days of age: exclude biliary atresia. Arch Dis Child. 1991;66(10): 1177–1179

8. Mieli-Vergani G, Howard ER, Portman B, Mowat AP. Late referral for biliary atresia: missed opportunities for effective surgery. Lancet. 1989;1(8635):421–423

9. Lee WS. Pre-admission consultation and late referral in infants with neonatal cholestasis. J Paediatr Child Health. 2008;44(1-2):57–61

10. Sokol RJ, Shepherd RW, Superina R, Bezerra JA, Robuck P, Hoofnagle JH. Screening and outcomes in biliary atresia: summary of a National Institutes of Health workshop. Hepatology. 2007;46(2):566–581

11. Lien TH, Chang MH, Wu JF, et al; Taiwan Infant Stool Color Card Study Group. Effects of the infant stool color card screening program on 5-year outcome of biliary atresia in Taiwan. Hepatology. 2011;53(1):202–208

12. Hopkins PC, Yazigi N, Nylund CM. Incidence of biliary atresia and timing of hepatoportoenterostomy in the United States. J Pediatr. 2017;187:253–257

13. Noorulla F, Dedon R, Maisels MJ. Association of early direct bilirubin levels and biliary atresia among neonates. JAMA Netw Open. 2019;2(10):e1913321

14. Suchy FJ. Neonatal cholestasis. Pediatr Rev. 2004;25(11):388–396

15. Feldman AG, Sokol RJ. Neonatal cholestasis: emerging molecular diagnostics and potential novel therapeutics. Nat Rev Gastroenterol Hepatol. 2019;16(6):346–360

16. Balistreri WF, Bezerra JA. Whatever happened to “neonatal hepatitis”? Clin Liver Dis. 2006;10(1):27–53, v

17. Dick MC, Mowat AP. Hepatitis syndrome in infancy: an epidemiological survey with 10 year follow up. Arch Dis Child. 1985;60(6):512–516

18. Gonzales E, Davit-Spraul A, Baussan C, Buffet C, Maurice M, Jacquemin E. Liver diseases related to MDR3 (ABCB4) gene deficiency. Front Biosci. 2009;14:4242–4256

19. Liu LY, Wang XH, Lu Y, Zhu QR, Wang JS. Association of variants of ABCB11 with transient neonatal cholestasis. Pediatr Int. 2013;55(2):138–144

20.Goldschmidt ML, Mourya R, Connor J, et al. Increased frequency of double and triple heterozygous gene variants in children with intrahepatic cholestasis. Hepatol Res. 2016;46(4):306–311

21. Satrom K, Gourley G. Cholestasis in preterm infants. Clin Perinatol. 2016;43(2):355–373

22. Hsieh MH, Pai W, Tseng HI, Yang SN, Lu CC, Chen HL. Parenteral nutrition-associated cholestasis in premature Babies: risk factors and predictors. Pediatr Neonatol. 2009;50(5):202–207

23. Lee WS, Sokol RJ. Intestinal microbiota, lipids, and the pathogenesis of intestinal failure-associated liver disease. J Pediatr. 2015;167(3): 519–526

24. Khalaf RT, Sokol RJ. New insights into intestinal failure-associated liver disease in children. Hepatology. 2020;71(4):1486–1498

25. Mittal V, Saxena AK, Sodhi KS, et al. Role of abdominal sonography in the preoperative diagnosis of extrahepatic biliary atresia in infants younger than 90 days. AJR Am J Roentgenol. 2011;196(4): W438–W445

26.Herbst SM, Schirmer S, Posovszky C, et al. Taking the next step forward - Diagnosing inherited infantile cholestatic disorders with next generation sequencing. Mol Cell Probes. 2015;29(5):291–298

27. Wang NL, Lu YL, Zhang P, et al. A specially designed multi-gene panel facilitates genetic diagnosis in children with intrahepatic cholestasis: simultaneous test of known large insertions/deletions. PLoS One. 2016;11(10):e0164058

28. Matte U, Mourya R, Miethke A, et al. Analysis of gene mutations in children with cholestasis of undefined etiology. J Pediatr Gastroenterol Nutr. 2010;51(4):488–493

29. Togawa T, Sugiura T, Ito K, et al. Molecular genetic dissection and neonatal/infantile intrahepatic cholestasis using targeted next generation sequencing. J Pediatr. 2016;171:171–7.e1, 4

30. Karpen S, Kamath B, Alexander J, et al. Use of a comprehensive 66 gene panel to diagnose the causes of cholestasis in >700 individuals [abstract 1213]. Hepatology. 2017;66(S1):655A.

31. Chardot C, Buet C, Serinet MO, et al. Improving outcomes of biliary atresia: French national series 1986-2009. J Hepatol. 2013;58(6): 1209–1217

32. Serinet MO, Wildhaber BE, Broue P, et al. Impact of age at Kasai operation on its results in late childhood and adolescence: a rational basis for biliary atresia screening. Pediatrics. 2009;123(5):1280–1286

33. Moyer V, Freese DK, Whitington PF, et al; North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Guideline for the evaluation of cholestatic jaundice in infants: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2004;39(2):115–128

34. Nievelstein RA, Robben SG, Blickman JG. Hepatobiliary and pancreatic imaging in children-techniques and an overview of non neoplastic disease entities. Pediatr Radiol. 2011;41(1):55–75

35. Kianifar HR, Tehranian S, Shojaei P, et al. Accuracy of hepatobiliary scintigraphy for differentiation of neonatal hepatitis from biliary atresia: systematic review and meta-analysis of the literature. Pediatr Radiol. 2013;43(8):905–919

36. Yang JG, Ma DQ, Peng Y, Song L, Li CL. Comparison of different diagnostic methods for differentiating biliary atresia from idiopathic neonatal hepatitis. Clin Imaging. 2009;33(6):439–446

37. Adeyemi A, States L, Wann L, Lin HC, Rand EB. Biliary excretion noted on hepatobiliary iminodiacetic acid scan does not exclude diagnosis of biliary atresia. J Pediatr. 2020;220:245–248

38. Zerbini MC, Gallucci SD, Maezono R, et al. Liver biopsy in neonatal cholestasis: a review on statistical grounds. Mod Pathol. 1997;10(8): 793–799

39. Russo P, Magee JC, Anders RA, et al; Childhood Liver Disease Research Network (ChiLDReN). Key histopathologic features of liver biopsies that distinguish biliary atresia from other causes of infantile cholestasis and their correlation with outcome: a multicenter study. Am J Surg Pathol. 2016;40(12):1601–1615

40.Russo P, Magee JC, Boitnott J, et al. Design and validation of the biliary atresia research consortium histologic assessment system for cholestasis in infancy. Clin Gastroenterol Hepatol. 2011;9(4):357–362e352. doi: https://doi.org/10.1016/j.cgh.2011.01.003

41. Hanquinet S, Courvoisier DS, Rougemont AL, et al. Contribution of acoustic radiation force impulse (ARFI) elastography to the ultrasound diagnosis of biliary atresia. Pediatr Radiol. 2015;45(10): 1489–1495

42. Leschied JR, Dillman JR, Bilhartz J, Heider A, Smith EA, Lopez MJ. Shear wave elastography helps differentiate biliary atresia from other neonatal/infantile liver diseases. Pediatr Radiol. 2015;45(3):366–375

43. Wu JF, Lee CS, Lin WH, et al. Transient elastography is useful in diagnosing biliary atresia and predicting prognosis after hepatoportoenterostomy. Hepatology. 2018;68(2):616–624

44. Jiang J, Wang J, Shen Z, et al. Serum MMP-7 in the Diagnosis of Biliary Atresia. Pediatrics. 2019;144(5):e20190902

45. Wu JF, Jeng YM, Chen HL, Ni YH, Hsu HY, Chang MH. Quantification of Serum Matrix Metallopeptide 7 Levels May Assist in the Diagnosis and Predict the Outcome for Patients with Biliary Atresia. J Pediatr. 2019;208:30–37.e1

46.Yang L, Zhou Y, Xu PP, et al. Diagnostic accuracy of serum matrix metalloproteinase-7 for biliary atresia. Hepatology. 2018;68(6): 2069–2077

47. Lertudomphonwanit C, Mourya R, Fei L, et al. Large-scale proteomics identifies MMP-7 as a sentinel of epithelial injury and of biliary atresia. Sci Transl Med. 2017;9(417):eaan8462

48. Harpavat S. MMP-7: The next best serum biomarker for biliary atresia? J Pediatr. 2019;208:8–9

49. Schreiber RA, Barker CC, Roberts EA, et al. Biliary atresia: the Canadian experience. J Pediatr. 2007;151(6):659–665, 665 e651. doi: https://doi.org/10.1016/j.jpeds.2007.05.051

50. Nio M, Ohi R, Miyano T, Saeki M, Shiraki K, Tanaka K; Japanese Biliary Atresia Registry. Five- and 10-year survival rates after surgery for biliary atresia: a report from the Japanese Biliary Atresia Registry. J Pediatr Surg. 2003;38(7):997–1000

51. Lykavieris P, Chardot C, Sokhn M, Gauthier F, Valayer J, Bernard O. Outcome in adulthood of biliary atresia: a study of 63 patients who survived for over 20 years with their native liver. Hepatology. 2005;41(2):366–371

52. Shneider BL, Brown MB, Haber B, et al; Biliary Atresia Research Consortium. A multicenter study of the outcome of biliary atresia in the United States, 1997 to 2000. J Pediatr. 2006;148(4):467–474

53. Sundaram SS, Mack CL, Feldman AG, Sokol RJ. Biliary atresia: indications and timing of liver transplantation and optimization of pretransplant care. Liver Transpl. 2017;23(1):96–109

54. Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl JMed. 1976;294(24):1316–1321

55. Townsend SA, Edgar RG, Ellis PR, Kantas D, Newsome PN, Turner AM. Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease. Aliment Pharmacol Ther. 2018;47(7):877–885

56. Teckman J, Rosenthal P, Hawthorne K, et al; ChiLDReN (Childhood Liver Disease Research Network). Longitudinal outcomes in young patients with alpha-1-antitrypsin deficiency with native liver reveal that neonatal cholestasis is a poor predictor of future portal hypertension. J Pediatr. 2020;227:81–86.e4

57. Kamath BM, Ye W, Goodrich NP, et al; Childhood Liver Disease Research Network (ChiLDReN). Outcomes of Childhood Cholestasis in Alagille Syndrome: Results of a Multicenter Observational Study. Hepatol Commun. 2020;4(3):387–398

58. Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA. Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology. 1999;29(3):822–829

59. Christensen RD, Henry E, Wiedmeier SE, Burnett J, Lambert DK. Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease. J Perinatol.

2007;27(5):284–290

60.Hoang V, Sills J, Chandler M, Busalani E, Clifton-Koeppel R, Modanlou HD. Percutaneously inserted central catheter for total parenteral nutrition in neonates: complications rates related to upper versus lower extremity insertion. Pediatrics. 2008;121(5):e1152–e1159

61. Pichler J, Horn V, Macdonald S, Hill S. Intestinal failure-associated liver disease in hospitalised children. Arch Dis Child. 2012;97(3):211–214

62. Abi Nader E, Lambe C, Talbotec C, et al. Outcome of home parenteral nutrition in 251 children over a 14-y period: report of a single center. Am J Clin Nutr. 2016;103(5):1327–1336

63. Spencer AU, Neaga A, West B, et al. Pediatric short bowel syndrome: redefining predictors of success. Ann Surg. 2005;242(3):403–409, discussion 409–412

64. El Kasmi KC, Anderson AL, Devereaux MW, et al. Phytosterols promote liver injury and Kupffer cell activation in parenteral nutrition-associated liver disease. Sci Transl Med. 2013;5(206): 206ra137